Publications by authors named "Judit Julian"
The use of noninvasive biomarkers may reduce the need for biopsy and guide immunosuppression adjustments during transplantation. The scientific community in solid organ transplantation currently considers that chemokines, T- and B-cell immunophenotypes, and gene expression, among other molecular biomarkers, have great potential as diagnostic and predictive biomarkers for graft evolution; however, in clinical practice, few valid early biomarkers have emerged. This review focuses on the most relevant scientific advances in this field in the last 5 years regarding the role of 3 biomarkers: miRNAs, chemokines, and ddcf-DNA, in both adult and pediatric populations.
View Article and Find Full Text PDFArticle Synopsis
- - Tacrolimus is crucial for preventing acute graft-versus-host disease (GVHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT), and genetic factors can influence how patients metabolize this drug.
- - In a study of 62 Caucasian alloHSCT recipients, it was found that the majority (79%) were poor metabolizers, and those with a faster metabolic phenotype had lower Tac concentrations and a higher incidence of acute GVHD.
- - The findings suggest that genetic testing could help doctors determine the right Tac dose for patients, potentially leading to better outcomes by reaching therapeutic levels faster and reducing GVHD risk.
Introduction: Mindray MC-80 is an automated system for digital imaging of white blood cells (WBCs) and their pre-classification. The objective of this work is to analyse its performance comparing it with the CellaVision® DM9600.
Methods: A total of 445 samples were used, 194 normal and 251 abnormal: acute leukaemia (100), myelodysplastic syndromes/myeloproliferative neoplasms (33), lymphoid neoplasms (50), plasma cell neoplasms (14), infections (49) and thrombocytopenia (5).
Introduction: The use of noninvasive biomarkers may avoid the need for liver biopsy (LB) and could guide immunosuppression adjustment in liver transplantation (LT). The aims of this study were: to confirm the predictive and diagnostic capacity of plasmatic expression of miR-155-5p, miR-181a-5p, miR-122-5p and CXCL-10 for assessing T-cell mediated rejection (TCMR) risk; to develop a score based on a panel of noninvasive biomarkers to predict graft rejection risk and to validate this score in a separate cohort.
Methods: A prospective, observational study was conducted with a cohort of 79 patients followed during the first year after LT.